Zachary Rosol, MD
Interventional Cardiology · Dallas, TXNPI 1417290156
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Shockwave Medical, Inc at 28.3% of the total. 2025 is the largest year on record at $21,971, 6.6 times the $3,314 reported in 2019.
Across 350 payments — averaging $193.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$19K
- Boston Scientific$16K
- Penumbra, Inc.$13K
- Biotronik Inc.$7K
- Medtronic$7K
- Angiodynamics, Inc.$1K
- plus $4K from 28 others
Across 26 payments — averaging $7281.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Penumbra, Inc.$143K
- Angiodynamics, Inc.$46K
What the payments were for
- Speaking & faculty fees$39,92559%
- Travel & lodging$10,93916%
- Food & beverage$16,61625%
- Education$1480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 39 | $19,134 |
| Boston Scientific | 62 | $16,472 |
| Penumbra, Inc. | 12 | $12,672 |
| Biotronik Inc. | 14 | $7,254 |
| Medtronic(2 entities) | 121 | $7,024 |
| Angiodynamics, Inc. | 8 | $1,207 |
| Teleflex LLC | 7 | $777 |
| Abbott | 8 | $758 |
| W. L. Gore & Associates, Inc. | 5 | $323 |
| Spectrawave, Inc | 5 | $310 |
| Pfizer | 7 | $179 |
| Johnson & Johnson | 8 | $146 |
| Cardiovascular Systems Inc. | 2 | $125 |
| Bard Peripheral Vascular, Inc. | 1 | $125 |
| Terumo Medical Corporation | 5 | $116 |
| Tactile Systems Technology Inc | 5 | $102 |
| Heartflow, Inc. | 3 | $94 |
| Cardinal Health 200 LLC | 2 | $92 |
| Merck | 5 | $89 |
| E.r. Squibb & Sons, L.L.C. | 5 | $88 |
| Imperative Care, Inc | 2 | $86 |
| Edwards Lifesciences | 2 | $84 |
| Novartis | 4 | $72 |
| Amgen | 4 | $54 |
| AstraZeneca | 3 | $47 |
| Abiomed | 1 | $42 |
| Boehringer Ingelheim | 2 | $32 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $23 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $18 |
| Recor Medical Inc | 1 | $17 |
| Vital Connect, Inc | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$18,358
- Indigo System$12,645
- GENERAL VASCULAR ACCESS$11,496
- CROSSBOSS$2,205
- CoreValve Evolut$1,783
- AlphaVac$1,080
- SYMPLICITY G3$757
- COREVALVE EVOLUT R$549
- AVVIGO Guidance System$535
- Resolute$457
- Orsiro Mission$391
- IN.PACT Admiral$325
- ONYX FRONTIER$320
- GUIDELINER$273
- MANTA$207
- HyperVue Imaging System$196
- Starlight Imaging Catheter$196
- XIENCE SIERRA$185
- Pulsar-18 T3$175
- HawkOne$166
How this compares
$67,628 in reported general payments places this provider in the 85th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 113 | $100,245 |
| EntrestoSacubitril/Valsartan | 58 | $71,621 |
| XareltoRivaroxaban | 57 | $55,301 |
| Repatha SureclickEvolocumab | 57 | $52,895 |
| FarxigaDapagliflozin Propanediol | 29 | $34,992 |
| Repatha SyringeEvolocumab | 44 | $18,883 |
| Praluent PenAlirocumab | 14 | $8,601 |
| Rosuvastatin Calcium | 290 | $3,985 |
| Atorvastatin Calcium | 217 | $2,275 |
| ClopidogrelClopidogrel Bisulfate | 204 | $2,237 |
| Ezetimibe | 104 | $1,729 |
| Cilostazol | 85 | $1,661 |
| Losartan Potassium | 133 | $1,401 |
| Metoprolol Succinate | 119 | $1,355 |
| Nitro-BidNitroglycerin | 16 | $1,037 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $179 | $100,245113 claims |
| NovartisEntresto | $72 | $71,62158 claims |
| Johnson & JohnsonXarelto | $146 | $55,30157 claims |
| AstraZenecaFarxiga | $47 | $34,99229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Dallas
- Robert StolerDallas$587K
- Byung ParkDallas$236K
- James ChoiDallas$211K
- Tony DasDallas$187K
- Kenneth JohnsonDallas$113K
- Srinivas YallapragadaDallas$99K
- Wally OmarDallas$84K
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- Jeffrey CarrTyler$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.